Smartest Doc
Applicability of a risk score for prediction of the long-term (8-year) benefit of the implantable cardioverter-defibrillator
JACC - Journal of the American College of Cardiology, 06/14/2012
Barsheshet A et al. – These findings suggest that a simple risk score can identify patients who derive significant long–term benefit from primary implantable cardioverter–defibrillator (ICD) therapy. High–risk patients with multiple comorbidities composed 17% of the MADIT–II population and did not derive long–term benefit from nonresynchronization device therapy.
